SYNTHETIC HYPERGLYCOSYLATED, PROTEASE-RESISTANT POLYPEPTIDE VARIANTS, ORAL FORMULATIONS AND METHODS OF USING THE SAME

• US 20100099851A1
• Filed: 10/19/2009
• Published: 04/22/2010
• Est. Priority Date: 08/09/2004
• Status: Abandoned Application

• Current Assignee: Alios Biopharma, Inc. (Johnson & Johnson)
• Original Assignee: Alios Biopharma, Inc. (Johnson & Johnson)
• Inventors: Hong, Jin, Seiwert, Scott D., Blatt, Lawrence M.
• Application Number:
  US12/581,723
• Publication Number:
  US 20100099851A1
• Time in Patent Office: Days
• US Class Current: 530/351
• CPC Class Codes: A61K 38/212 IFN-alpha
• CPC Class Codes: A61P 19/04 for non-specific disorders of the connective tissue
• CPC Class Codes: A61P 31/12 Antivirals
• CPC Class Codes: A61P 31/14 for RNA viruses
• CPC Class Codes: A61P 35/00 Antineoplastic agents

Abstract

The present invention provides synthetic Type I interferon receptor polypeptide agonists comprising consensus or hybrid Type I interferon receptor polypeptide agonists, containing one or more native or non-native glycosylation sites. The present invention further provides oral formulations of protease-resistant or protease-resistant, hyperglycosylated polypeptide variants, which polypeptide variants lack at least one protease cleavage site found in a parent polypeptide, and thus exhibit increased protease resistance compared to the parent polypeptide, which polypeptide variants further include (1) a carbohydrate moiety covalently linked to at least one non-native glycosylation site not found in the parent protein therapeutic or (2) a carbohydrate moiety covalently linked to at least one native glycosylation site found but not glycosylated in the parent protein therapeutic. The present invention further provides compositions, including oral pharmaceutical compositions, comprising the synthetic Type I interferon receptor polypeptide agonist, the hyperglycosylated polypeptide variant, the protease-resistant polypeptide variant, or the hyperglycosylated, protease-resistant polypeptide variant. The present invention further provides containers, devices, and kits comprising the synthetic Type I interferon receptor polypeptide agonist, the hyperglycosylated polypeptide variant, the protease-resistant polypeptide variant, or the hyperglycosylated, protease-resistant polypeptide variant. The present invention further provides therapeutic methods involving administering an effective amount of an oral pharmaceutical composition comprising a synthetic Type I interferon receptor polypeptide agonist, a hyperglycosylated polypeptide variant, a protease-resistant polypeptide variant, or a hyperglycosylated, protease-resistant polypeptide variant to an individual in need thereof.

Claims

1. A hyperglycosylated Type I interferon variant of a parent Type I interferon, wherein the hyperglycosylated Type I interferon is the parent Type I interferon that has been modified to include at least two additional glycosylation sites, wherein at least one of the additional glycosylation sites is introduced by an amino acid substitution at a position selected from amino acid position 99, 105 and 134, wherein the positions of the amino acid substitutions are with reference to sequence alignment numbering set forth in FIG. 24.

2. The hyperglycosylated Type I interferon variant of claim 1, wherein at least one additional glycosylation site is introduced by an amino acid substitution selected from the group consisting of [D99N], [S99N], [R99N], [D105N], [E134N], [E134T], [G134N], [G134T] and [F136T].

3. The hyperglycosylated Type I interferon variant of claim 1, wherein the hyperglycosylated Type I interferon variant comprises at least three additional glycosylation sites.

4. The hyperglycosylated Type I interferon variant of claim 3, wherein at least two additional glycosylation sites are introduced by amino acid substitutions selected from the group consisting of [D99N], [S99N], [R99N], [S101T], [D105N], [E134N], [E134T], [G134N], [G134T] and [F136T].

5. The hyperglycosylated Type I interferon variant of claim 1, wherein the parent Type I interferon is an interferon α

(IFN-α

).

6. The hyperglycosylated Type I interferon variant of claim 5, wherein the interferon a (IFN-α

) is selected from the group consisting of interferon-α

2a, interferon-α

2b and consensus interferon α

.

7. The hyperglycosylated Type I interferon variant of claim 6, wherein the consensus interferon α

is interferon alfacon-1.

8. The hyperglycosylated Type I interferon variant of claim 7, wherein the hyperglycosylated Type I interferon variant is interferon alfacon-1 comprising at least an amino acid substitution selected from the group consisting of [D99N], [D105N], [E134N], [E134T], [D99N, D105N], [D99N, E134N], [D99N, E134T], [D105N, E134N], [D105N, E134T], [D99N, D105N, E134N], and [D99N, D105N, E134T].

9. The hyperglycosylated Type I interferon variant of claim 7, wherein the hyperglycosylated Type I interferon variant is interferon alfacon-1 comprising at least the amino acid substitution [D99N].

10. The hyperglycosylated Type I interferon variant of claim 7, wherein the hyperglycosylated Type I interferon variant is interferon alfacon-1 comprising at least the amino acid substitution [D105N].

11. The hyperglycosylated Type I interferon variant of claim 7, wherein the hyperglycosylated Type I interferon variant is interferon alfacon-1 comprising at least the amino acid substitution [E134N].

12. The hyperglycosylated Type I interferon variant of claim 7, wherein the hyperglycosylated Type I interferon variant is interferon alfacon-1 comprising at least the amino acid substitution [E134T].

13. The hyperglycosylated Type I interferon variant of claim 7, wherein the hyperglycosylated Type I interferon variant is interferon alfacon-1 comprising at least the amino acid substitutions [D99N] and [D105N].

14. The hyperglycosylated Type I interferon variant of claim 7, wherein the hyperglycosylated Type I interferon variant is interferon alfacon-1 comprising at least the amino acid substitutions [D99N] and [E134N].

15. The hyperglycosylated Type I interferon variant of claim 7, wherein the hyperglycosylated Type I interferon variant is interferon alfacon-1 comprising at least the amino acid substitutions [D99N] and [E134T].

16. The hyperglycosylated Type I interferon variant of claim 7, wherein the hyperglycosylated Type I interferon variant is interferon alfacon-1 comprising at least the amino acid substitutions [D99N], [S101T], and [E134T].

17. The hyperglycosylated Type I interferon variant of claim 7, wherein the hyperglycosylated Type I interferon variant is interferon alfacon-1 comprising at least the amino acid substitutions [D105N] and [E134N].

18. The hyperglycosylated Type I interferon variant of claim 7, wherein the hyperglycosylated Type I interferon variant is interferon alfacon-1 comprising at least the amino acid substitutions [D105N] and [E134T].

19. The hyperglycosylated Type I interferon variant of claim 7, wherein the hyperglycosylated Type I interferon variant is interferon alfacon-1 comprising at least the amino acid substitutions [D99N], [D105N], and [E134N].

20. The hyperglycosylated Type I interferon variant of claim 7, wherein the hyperglycosylated Type I interferon variant is interferon alfacon-1 comprising at least the amino acid substitutions [D99N], [D105N], and [E134T].